Lifitegrast is a FDA approved drug for the treatment of keratoconjunctivitis sicca (dry eye syndrome). It is a tetrahydroisoquinoline derivative and lymphocyte function-associated antigen-1 ( LFA-1) antagonist that was discovered through the rational design process. The ophthalmic solution was approved in July, 2016 under the trade name Xiidra. It has shown ...
适用于治疗干眼病(DED)的症状和体征。
Centre for Ocular Research & Education, Waterloo, Ontario, Canada
Toyos Clinic, Nashville, Tennessee, United States
Piedmont Eye Center /ID# 232698, Lynchburg, Virginia, United States
Cornea and Cataract Consultants of Arizona /ID# 232769, Phoenix, Arizona, United States
Total Eye Care, PA /ID# 232657, Memphis, Tennessee, United States
Harvard Eye Associates, Laguna Hills, California, United States
Eye & Vision, Richardson, Texas, United States
Lifelong Vision Foundation, Chesterfield, Missouri, United States
University of Alabama at Birmingham, Birmingham, Alabama, United States
Chicago Cornea Consultants, Ltd., Hoffman Estates, Illinois, United States
Jackson Eye, SC, Lake Villa, Illinois, United States
Lifelong Vision Foundation, Chesterfield, Missouri, United States
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.